Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases
Диагностика и лечение заболеваний печени, связанных с употреблением алкоголя: практические рекомендации Американской ассоциации по изучению заболеваний печени, 2019 г.
2019-07-17
SCID: 54.1/cp9847jv
Discuss with AI
acute-on-chronic liver failurealcohol-associated cirrhosisalcohol-associated liver diseasealcohol-associated steatohepatitisalcoholic hepatitis
Figures from the paper
Abstract (AI)
Supported by the American Association for the Study of Liver Diseases. Potential conflict of interest: Dr. Lucey received grants from Gilead, AbbVie and Pharmasolutions. Dr. Szabo consults and received grants from Allergan. She consults for Terra Firma, Glympse, Quest, Arrow, GLG, Salix and Tobira. She received grants from Gilead, Genfit, Intercept, Verlyx, Novartis, SignaBlok and Shire. She holds intellectual property rights with Up to Date. Purpose and Scope of the Guidance Alcohol‐associated liver disease (ALD) represents a spectrum of liver injury resulting from alcohol use, ranging from hepatic steatosis to more advanced forms including alcoholic hepatitis (AH), alcohol‐associated cirrhosis (AC), and acute AH presenting as acute‐on‐chronic liver failure. ALD is a major cause of liver disease worldwide, both on its own and as a co‐factor in the progression of chronic viral hepatitis, nonalcoholic fatty liver disease (NAFLD), iron overload, and other liver diseases. ALD develops through several stages, beginning with hepatic steatosis, and, in some individuals, gradually progressing through AH (the histological correlate of which is alcoholic steatohepatitis), culminating in cirrhosis (Fig. 1).1 Progression through these various stages is dependent on continued heavy alcohol use and other risk factors, including female sex, genetic susceptibility, diet, and comorbid liver disease. ALD carries a significant stigma in society. It is increasingly recognized by providers that patients and their families seek to reduce the stigma of ALD, and a change from the term “alcoholic” to “alcohol‐associated” will help; thus, alcohol‐associated liver disease, alcohol‐associated steatohepatitis, and alcohol‐associated cirrhosis are suggested, retaining the familiar abbreviations (ALD, ASH, and AC, respectively). Due to longstanding usage, the term “alcoholic hepatitis” will likely persist.Figure 1: Natural history of alcohol‐associated liver disease. Images courtesy of Dr. M. Isabel Fiel.This 2019 ALD Guidance provides a data‐supported approach to the prevalence, clinical spectrum, diagnosis, and clinical management of ALD and alcohol use disorders (AUDs). The Guidance was developed by consensus of an expert panel and provides guidance statements based on formal review and analysis of published literature on the topics. The quality (level) of the evidence and the strength of each guidance statement are not formally rated. Updates to the 2010 Guideline include an emphasis on AUD definition, screening, and treatment; new alcohol biomarkers; additional genetic and environmental susceptibility factors; a consensus definition of AH, and review of recent studies of corticosteroids and guidance on the role of transplantation in the management of AH. Prevalence and Burden of Alcohol‐Associated Liver Disease Alcohol‐associated liver disease includes a variety of clinical disorders: steatosis, ASH, AH of varying degrees of severity, AC, and AC complicated by hepatocellular carcinoma (HCC). ALD comprises a substantial portion of the overall cirrhosis burden, both in the United States and worldwide, and is responsible for rising rates of liver‐related mortality in the United States, especially among younger patients.3 In the United States, mortality due to all ALD was estimated at 5.5 per 100,000 in 2012; the relative contribution of ALD to all cirrhosis mortality is predicted to increase as the proportion of deaths due to hepatitis C virus (HCV) cirrhosis declines.3 More recently, AC mortality was shown to have increased from 2008 to 2016, particularly among patients ages 25‐34 years old.4 Cirrhotic and noncirrhotic ALD prevalence has been estimated at approximately 2% in the general US population, whereas AC in the US Veterans' population was estimated at 327 per 100,000 enrollees.7 In privately insured US patients, AC has been estimated at approximately 100 per 100,000 enrollees, and, overall, rates are projected to rise over time.3 Worldwide, AC deaths account for about 10% of all alcohol‐attributable deaths, and nearly half of those deaths are due to liver disease, resulting in the loss of 22.2 million disability‐adjusted life years annually.10 In the United States, ALD competes with chronic HCV as the leading indication for liver transplantation (LT).12 Medical costs are high for AC, driven in part by the higher number of admissions for these patients.9 In addition, deaths related to alcohol use are frequently underestimated due to the stigma of alcohol use and lack of candor in reporting.10 In women, AC prevalence may be increasing at a faster rate than in men, mirroring the rise in alcohol use in women in the United States.9 The incidence of AH has been difficult to estimate, as diagnostic accuracy of administrative coding is less reliable for AH.15 The incidence of AH varies worldwide. In the United States, admissions for AH were found to have increased to 0.83% of all admissions for 2010.13 In Denmark, the incidence of AH for the period 1999‐2008 rose from 37 to 46 per million persons per year in men and 24 to 34 per million persons per year for women.17 A similar study in Finland reported increased incidence rates for AH from 37 to 65 cases per million persons per year for men and from 13 to 27 cases per million persons per year for women.18 In both of these cases, estimates were based on diagnostic coding, which may be less accurate and highlights the difficulty in estimating the burden of AH. Accurate assessment of the full spectrum of ALD prevalence is challenging, particularly given the difficulty with identifying earlier, asymptomatic stages of ALD, such as ASH AH, that may be with use of steatosis and assessment and increased for the to disease. studies the prevalence and burden by as ALD those patients additional liver such as in of the that ALD rates are as high as in some patients with other liver in nonalcoholic and may in as as a for of of the and the of alcohol and have been by the term use as based on the of and use is in the United States, with significant more forms of by alcohol to and the of alcohol are on the of AUD and have with the prevalence of AUD in of US increasing by and with reported among women, and those of The of alcohol and the prevalence of more more over the period with substantial for of and Worldwide, alcohol varies with the rates of reported per alcohol in and and for in the is in over a period than The of at of these an more is a to alcohol A of is in to use from its a to use alcohol use resulting in a to major role at alcohol use by the of are given of alcohol alcohol use in in which is use is continued of a that is likely to have been by as of the for increased of alcohol to with continued use of the of as by of the The alcohol a related such as a is to and to The approach to the of alcohol use is and to with for and the of alcohol of alcohol use be for patients, may a and and and of The of AUD and ALD may not be particularly in stages of The on and has published a for to alcohol use more and more cases to for on to general than patients with ALD is of alcohol for patients with the US has published its in and and The statement for alcohol use in in years including women, and persons in with to reduce alcohol to alcohol use are by the use of The a in the year have more in a more in a is the definition of in in women over the a the is The is and is by the on and alcohol‐associated with a than of alcohol use, and than of alcohol are (the as a more of for alcohol use, not on more alcohol use The is and than the and other in identifying alcohol of at may alcohol not a of to the for a formal The and to for the general a more of in general and has been shown to patients with ALD and by with a of the for liver disease, may be for alcohol alcohol use of and in the heavy ALD diagnosis, and to of use of such as has been shown to as as the to clinical including for alcohol‐associated of of alcohol use to in which of alcohol use and an estimated of recent The American of and American Association the use of alcohol as an to diagnosis, to and as for with the than as to of use include use with patients to and alcohol use of the alcohol has not be on their own to alcohol use, be with other other alcohol and the clinical evidence of may alcohol use, on their own are to alcohol use in is an found in the of several including liver and is frequently in heavy and has than is not for alcohol is as a of alcohol of reported as the of per to account for in has a of The of is by its of in several studies and by in patients with liver disease in the of alcohol use of to be more likely due to liver A of alcohol is by and and are in the are found in and and have been and of for of alcohol use were and among patients with ALD and studies in patients with of liver disease, including found of and for of the for and with higher of and and be in resulting in a of alcohol in patients with disease. is a by the of with by in the has a of approximately be with more heavy alcohol and not to be by sex, disease, liver may have higher for a given of alcohol with are in has been in a study of chronic liver disease patients not at a of for per more with a of and of study of use in patients with ALD and a of and of for a of over The of the for alcohol use are given in and of of in Liver and of and and of significant to More than all studies the that with alcohol studies on patients than and of of in Liver of in with Liver Disease and Liver and Guidance patients in and and admissions be for alcohol use and to be to patients in be to in and and and are not by liver disease, and are of is the in from ALD, management with and to for particularly in patients with to ALD, is a review of of with a on that have been in patients with patients, will be to a patients are about alcohol has been shown to patients change including alcohol A new developed by is to and their families AUD and through an and the and to in with ALD are a variety of alcohol use to patients, have been in patients with of include alcohol and as various of are that of include and has been in a in A recent review of in ALD found that AUD providers providers in rates than which a to a the liver of AUD in both and include and with in varying in each were of which patients with AC and of which significant with an alcohol use with studies for patients with HCV and AUD and in with are to that is to all of on these the for management of advanced ALD and may not be in all for includes both and and in are and The number to to to is estimated to be approximately for and for and hepatic and cause liver whereas has hepatic of these have been in patients with AH and In addition, are several with some in that have not been for AUD include and a is the AUD that has been in an in patients with AC with AUD as as in In a of patients with both and AC, a of in rates of alcohol and with the year of an patients with hepatic were from as may a that may be in more advanced liver disease. on and in the of an not to be to the liver and is in Liver Disease and of ALD in patients with ALD in patients with ALD reported of through at in patients with ALD for and in patients with ALD in patients with ALD from for AUD is not on is not for use in patients with and per Guidance to AUD is for patients with advanced ALD to to the full of AUD management of ALD and AUD is and rates of alcohol among patients with on the use of be for the of AUD in patients with and for Alcohol‐Associated Liver Disease the of heavy alcohol use worldwide, is that a of heavy significant liver disease. The of alcohol on the liver is not is a which the risk for liver disease with increasing of to the for US of and and US of the of to be per for women and for the as a of that alcohol to and that for women and for men, in about The and which the on and an definition at in the definition, a alcohol to A be to the that of of alcohol is by The of to be with a recent analysis that alcohol use be to per for men and women, that may have The of ALD is alcohol use in of through on the of the liver and on a number of that in fatty and In some individuals, in to increased of the and liver and and through and among the and of these has in in liver and these with and are and the that the risk of alcohol‐associated liver have a risk of liver injury with men for of was less likely to be with cirrhosis than other risk of ALD, and the risk for A of studies of alcohol and cirrhosis risk increased risk for is evidence that the risk of cirrhosis of including ALD as as the of Liver Disease in increasing the risk of alcohol‐associated liver injury of of with men of comorbid chronic viral hepatitis, in the risk of alcohol‐associated liver injury on the risk of alcohol‐associated liver injury of alcohol alcohol use in patients with high in studies of genetic of a risk will be with increased risk with the thus, each of these are as in increasing of a of about for and studies to be a in the alcohol and have been to risk of not with risk of liver in the for the alcohol a risk for of and have shown that are at increased risk of ASH, and and of AH with and have been with risk of has been with risk of AC and AH, as have in the and and are with increased risk of in recently, a related to a hepatic 13 the of which the progression from steatosis to in alcohol‐associated and chronic liver heavy alcohol use by patients with other liver the of advanced and The are and alcohol use in may and risk of the of the were found to be risk for alcohol‐associated liver The alcohol use and progression of HCV disease is A recent study that the patients with increased risk of liver for and liver‐related use was with a increased risk of cirrhosis in patients with Guidance liver disease be about of alcohol use for men more than per 24 and women more than per 24 with ALD other liver in viral hepatitis, and be that is of and that and of Alcohol‐Associated Liver is of ALD that be with from other forms of liver disease. use is not by the whereas liver due to alcohol other not all patients with ALD the for to AUD a significant clinical to have a high of for AUD in patients presenting with and given in and Liver Disease of alcohol on by at to loss to loss of part of hepatic of of especially alcohol in men for Alcohol‐Associated with alcohol‐associated steatosis are A liver may be found in the of of advanced liver disease. the liver of and are the of recent alcohol steatosis is on and of the is more accurate for than other with the that over the of the Liver is for the of alcohol‐associated of of with to the with thus, that and alcohol use are Alcohol‐associated steatosis is with of alcohol Alcohol‐Associated is at the of may be in the of and are in may hepatic of and may evidence of increased liver AC be from other of cirrhosis through of history and of other of liver disease. The of AC is as other forms of the and the for Liver Disease The of AC is by the to both to the progression of and its and in of for It is to that of a with cirrhosis may the of AH, as patients with AH have developed thus, an for may be is a spectrum of clinical of patients with AH may with liver failure. AH per is a clinical are and in with a The histological of AH may be in patients with and histological of in and steatosis, and these are in cases, and are with In addition, liver ASH and The role of liver is to diagnostic and to AH in patients to clinical in a number of patients, a consensus statement the clinical of AH, and of ASH was was published in The statement was to in of AH studies and clinical and to clinical about the use of such as corticosteroids (Fig. It patients with AH those with AH, those with AH, and those with AH of histological of for alcoholic AH, alcoholic and for AH are A study of a panel of of liver injury and in patients with AH that of and the of and both an the of to the of that may have that have diagnostic for AH In addition, may be in and liver the liver and the may have a role in in ALD, and in of with of these have been for clinical use in the of AH. Guidance The of AH be the published consensus in AH be to the and of AH and are the particularly those of the and are use to these with of the of in to in AH. The was from the of an clinical corticosteroids to and to patients with AH with high risk of mortality at the was at (Fig. In a of less than those with AH, not risk of mortality with The additional to patients a from corticosteroids and those has given the in and a in clinical of AH. not the United the has been shown to the of patients with an of at will from corticosteroids the number to of in corticosteroids a corticosteroids and of corticosteroids and and of in of in AH to in AH in for corticosteroids for corticosteroids and not of of patients with corticosteroids of United of corticosteroids with of patients with alcoholic hepatitis likely to from with liver hepatitis and the is at is less accurate in the and The and the more and more by and be at is liver these may a not in patients with AH, among patients on the the over progression of liver disease and additional increasing risk of whereas a a in the for corticosteroids has not been for a of at has been The as a by the change in at corticosteroids to and the of its for by the than and of corticosteroids and of clinical the has been shown to have similar to corticosteroids approach additional and to in AH, that the of other such that for a with a of and of a higher risk of at than with a of and of of by the change of disease an and may and the of clinical are liver AH The was and in a that includes of of of and of the predicted and high risk of mortality with an of are about the of liver and significant among its In a study to in liver with clinical the the of with the patients with and with an of and other including new was in an is not for with liver on a of patients with AH, such are to in AH The of that with patients with AH at high risk for acute injury due to The of is in the of in the AH in to in AH include the of and and the use of of for with and is with of and high mortality in AH, in disease, and be in AH The in AH were and in a significant proportion of patients with AH are for these may not other to the of AH. are in AH with prevalence at the of with to half at some and are with the risk of and as the of at with and the of liver in is and by the in the from alcohol is the of in patients with AH in AH include to alcohol AH has been given to the diagnosis, and of patients with AH not these for AH. patients be as AH be as a is for these patients, on the of disease, and management of these patients with AUD to alcohol the that patients with chronic alcohol use to providers at the of of ALD and of progression to AC be a management in both the as as in studies are to the history of AH with to its to AH and its to the of cirrhosis in the of AH. Guidance be to in AH. The be to the for with corticosteroids other A than of from alcohol be to in AH. of AH of alcohol use in the of AH in increased rates of hepatic and risk of and patients with ALD be to from alcohol use, which alcohol over based on a may be in some of has been for as patients with AH are are by of for AH in hepatic and for higher quality A recent to received additional of with of and of than was with increased rates of and mortality at than those with higher with has on those the with AH C and and A found evidence for in these and a of to corticosteroids in the patients with chronic alcohol and AH are has been shown to to the in of ALD and in clinical of the role of in AH, use of of be in and AH. In AC, recent of have not shown are the in AH, with more than clinical including a more than have with a high risk of due to and lack of to in the of studies and the of is the mortality of AH over ranging from at in with more recently, several have the of which In the mortality at with a risk The in AH is the for a that patients with AH in the United over The study not a significant at in patients corticosteroids with on a corticosteroids were with not at The of liver of and than mortality in the may have the of the study to a of corticosteroids The of patients with to and use of may have the of The which for a The with the for not for as in the (Fig. a study in patients with AH with than corticosteroids were found to have with a which corticosteroids are study was not to at higher and studies have not The from that patients with AH in the similar to to those with that patients based on in the of from patients with high on of the have disease, which assessment for and other to for to are several relative to use in AH (Fig. and are in AH and have clinical providers and a on with is to for other of be to for the of other to with and the of the from to from the and the was of in the of in AH is and is in a clinical is be have been of resulting in high particularly in patients with AH in and has not been reported in the United these the of has not been shown to be a of the to corticosteroids based on the is with as a of liver the of has been an in AH clinical the evidence for corticosteroids in patients with is be be The of in patients with AH is in an with have been in clinical in AH. In a study of patients with AH, with and the were given and patients at a of the patients a incidence of likely due to were in at and the study that is not an for and that of be given of Potential In an in of with corticosteroids some with corticosteroids the mortality with was not at mortality was the the study was a in of the The and were the as those for the of and acute liver A recent of the of corticosteroids risk In be as and liver A study with for in AH significant in and mortality at with the is on the of its to hepatic than of more study patients of for clinical studies of the and of transplantation have been reported to liver and in patients with be for of and The use of in AH was by an to a have to have shown a in the of in patients with AH received from to a of as a in in with with the by evidence of the and the of have to of of and in patients with AH, were due to mortality in the was in a that not with of of various including and and and and have to in The of ALD with fatty driven by provides the for of developed for In addition, a major from the has with the of identifying new and clinical studies to and new for to in AH, including leading to and in the and hepatocellular and Guidance given be to mortality in patients with AH to the use of corticosteroids The of to may the of patients with AH. The be to and of with AH have and with is to for of be to increase is in the of AH. Liver for ALD Prevalence of for ALD ALD is a leading indication for patients in the United States, HCV in with HCV ALD for of all in the United States from to a by expert in the United States and the number of new with ALD increased by from to The of patients with ALD from is patients with ALD are for to those with other liver be among the general and general that AUD and ALD are due to of about the risk of and and the of of likely reduce the of ALD, particularly with less and In the clinical AC, such as acute‐on‐chronic liver due to recent alcohol use comorbid The of lack of to and high mortality the of of and of for for ALD The clinical that the that be are new an of of than with ALD to of particularly with C be and for The of patients with ALD for is among as the history of to alcohol is of the of alcohol use and the of and are by an expert in the Up recently, in the United States patients with ALD to be from alcohol for a of for the In a consensus of the and American of
Key Findings
1
ALD is a major global cause of liver disease and can accelerate progression of chronic viral hepatitis, NAFLD, iron overload, and other liver diseases.
2
Alcohol-associated liver disease spans hepatic steatosis, alcoholic hepatitis, alcohol-associated cirrhosis, and acute alcoholic hepatitis presenting as acute-on-chronic liver failure.
3
Disease progression depends on continued heavy alcohol use and additional factors including female sex, genetic susceptibility, diet, and comorbid liver disease.
4
The guidance recommends replacing stigmatizing terminology such as “alcoholic” with “alcohol-associated,” while recognizing that “alcoholic hepatitis” will likely persist because of longstanding usage.
Research Object
alcohol-associated liver disease (ALD)
Research Subject
the spectrum, progression, diagnosis, and treatment of alcohol-associated liver injury, including hepatic steatosis, alcoholic hepatitis, cirrhosis, and acute-on-chronic liver failure
Publication Details
Publication Date
2019-07-17
Journal
Hepatology
Publisher
Lippincott Williams & Wilkins
ISSN
0270-9139
Cited by
1033
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest